EP Patent

EP1828217A2 — Polymerase-independent analysis of the sequence of polynucleotides

Assigned to Febit Holding GmbH · Expires 2007-09-05 · 19y expired

What this patent protects

The present invention concerns methods of polymerase independent template directed elongation of polynucleotides, nucleotide building blocks used in these methods as well as the use of the methods and building blocks for the determination of nucleotide sequences, in particular fo…

USPTO Abstract

The present invention concerns methods of polymerase independent template directed elongation of polynucleotides, nucleotide building blocks used in these methods as well as the use of the methods and building blocks for the determination of nucleotide sequences, in particular for the determination of SNPs, base modifications, mutations, rearrangements and methylation patterns.

Drugs covered by this patent

Patent Metadata

Patent number
EP1828217A2
Jurisdiction
EP
Classification
Expires
2007-09-05
Drug substance claim
No
Drug product claim
No
Assignee
Febit Holding GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.